TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$368 Million

Adaptive Biotechnologies Corp.

Follow-on Offering

Passive Bookrunner, July 2020

Adaptive Biotechnologies Corp.

Adaptive is advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. The Company believes the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Adaptive’s immune medicine platform applies proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how it detects and treats disease in that patient. Adaptive captures these insights in its dynamic clinical immunomics database, which is underpinned by computational biology and machine learning, and uses them to develop and commercialize clinical products and services that are tailored to each individual patient. The Company has two commercial products and services and a robust pipeline of clinical products and services that are designed to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases.